HER3 expression and MEK activation in non-small-cell lung carcinoma-Reference-Cited by-同舟云学术

HER3 expression and MEK activation in non-small-cell lung carcinoma

Published:2021-06 Issue:2 Volume:10 Page:
ISSN:1758-1966
Container-title:Lung Cancer Management
language:en
Short-container-title:Lung Cancer Management

Author:

Manickavasagar Thubeena¹,Yuan Wei¹,Carreira Suzanne¹,Gurel Bora¹,Miranda Susana¹,Ferreira Ana¹,Crespo Mateus¹,Riisnaes Ruth¹,Baker Chloe¹,O’Brien Mary²,Bhosle Jaishree²,Popat Sanjay³,Banerji Udai¹,Lopez Juanita¹,Bono Johann de¹,Minchom Anna¹²^ORCID

Affiliation:

1. Drug Development Unit, Royal Marsden Hospital, Downs Road, Sutton, London, SM2 5PT, UK

2. Lung Unit, Royal Marsden Hospital, Sutton, SM2 5PT, UK

3. Lung Unit, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK

Abstract

Aim: We explore HER3 expression in lung adenocarcinoma (adeno-NSCLC) and identify potential mechanisms of HER3 expression. Materials & methods: Tumor samples from 45 patients with adeno-NSCLC were analyzed. HER3 and HER2 expression were identified using immunohistochemistry and bioinformatic interrogation of The Cancer Genome Atlas (TCGA). Results: HER3 was highly expressed in 42.2% of cases. ERBB3 copy number did not account for HER3 overexpression. Bioinformatic analysis of TCGA demonstrated that MEK activity score (a surrogate of functional signaling) did not correlate with HER3 ligands. ERBB3 RNA expression levels were significantly correlated with MEK activity after adjusting for EGFR expression. Conclusion: HER3 expression is common and is a potential therapeutic target by virtue of frequent overexpression and functional downstream signaling.

Publisher

Future Medicine Ltd

Subject

Pulmonary and Respiratory Medicine,Oncology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/lmt-2020-0031

Reference56 articles.

1. American Cancer Society. Lung cancer survival rates. (2019). https://www.cancer.org/cancer/lung-cancer/detection-diagnosis-staging/survival-rates.html

2. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

3. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.

4. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.

5. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance;Cancer Letters;2024-09

2. Plasma-Activated Media Produced by a Microwave-Excited Atmospheric Pressure Plasma Jet Is Effective against Cisplatin-Resistant Human Bladder Cancer Cells In Vitro;International Journal of Molecular Sciences;2024-01-19

3. Targeting HER3 to overcome EGFR TKI resistance in NSCLC;Frontiers in Immunology;2024-01-04

4. CD44s and CD44v8-10 isoforms confer acquired resistance to osimertinib by activating the ErbB3/STAT3 signaling pathway;Life Sciences;2024-01

5. Concordance between cryobiopsy and forceps biopsy specimens in assessment of immunohistochemistry staining for non-small cell lung carcinoma;Translational Lung Cancer Research;2023-06